34 results about "Binding free energy" patented technology

Novel methods for the treatment and / or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

The present invention provides a method of screening NRG mutant for activating ErbB acceptor specifically. The method includes the following steps: establishing 3D model of complex of NRG, ErbB3, ErbB4, NRG / ErbB3 and NRG / ErbB4 in a homogeneous model establishing process; molecular kinetically simulating conformation and stability of NRG / ErbB3 and NRG / ErbB4; MM / PBSA process of calculating the binding free energy between NRG and ErbB3 or ErbB4; scanning and calculating process based on alanine theory to determine the NRG and acceptor affinity change during the mutation from NRG residue to alanine and determining NRG mutant for activating ErbB acceptor specifically. The present invention also provides the NRG mutant and its application and preparation process.

The invention relates to a computing method for processing interaction between small molecules and proteins. The method includes the following steps that (1) ligand file data of the proteins and the small molecules are read in; (2) atom types in ligands of the proteins and the small molecules are judged; (3) positions and angles of the ligands of the small molecules are randomly initialized; (4) a search protein algorithm is operated, coordinates and angles of the ligands of the small molecules are optimized, and a chemscore formula serves as an evaluation function; (5) the computing is ended after maximum iterative times are achieved; and (6) results such as root mean square deviation (RMSD), binding free energy delta G and coordinates of a binding site are analyzed and output. Compared with computing methods for processing the interaction between the small molecules and the proteins in prior art, the computing method for processing the interaction between the small molecules and the proteins has the advantages that when pollutants and biomacromolecules are interacted can be rapidly determined, and the like.

The invention relates to methods of modulating the antigen-binding affinity of an antibody by determining, using data corresponding to the structure of a complex between the antibody and an antigen in a solvent, a representation of a charge distribution of the CDRs of the antibody which minimizes electrostatic contribution to binding free energy between the antibody and the antigen in a solvent. Guided by these determinations, the antibody is accordingly modified (altered) to improve upon, e.g., antibody / antigen binding by modifying at least one amino acid residue to decrease the binding free energy between the antibody and antigen when bound in a solvent.

The invention discloses a method, system, and device for calculating binding free energy of proteins and drugs, and a medium. The method includes the steps: constructing a function of the binding freeenergy of proteins and drugs, wherein the function of the binding free energy of the proteins and the drugs is a relationship between the binding free energy of the proteins and the drugs and an electrostatic item, a polar solvation energy item, a van der Waals item, a nonpolar solvation energy item and interaction entropy; collecting each energy item of each protein and each drug complex in a training set, and performing multivariate linear fitting on the function of the binding free energy of proteins and drugs by using each energy item of each protein and each drug complex in the trainingset and the experimental value of each protein and each drug to obtain a function of the binding free energy of the proteins and the drugs; and inputting each energy item of the proteins to be testedand the drug complex into the trained function of the binding free energy of proteins and drugs, and outputting the binding free energy of the proteins and the drugs.

The invention provides a protein-ligand free energy calculating method based on a MM / PBSA model. The method comprises the following steps of respectively acquiring pdb files of a protein and a ligandmolecule; preprocessing the pdb file of the protein by means of a pdb4amber tool, deleting a hydrogen atom which cannot be read by Amber software; for the pdb file of the ligand molecule, converting the pdb format to a mol2 file format by means of an antechamber tool, and correcting the atom type to the atom type of an amber force field; assigning a GAFF force field parameter of the ligand molecule by means of a tleap command; respectively generating a topological file and a coordinate file of the protein, the ligand micromolecule and a protein-ligand micromolecule composite structure by meansof the tleap command through using an AMBER99SB-ILDN molecule force field parameter, and adding a water box and counter ions in the process; performing energy minimizing, heating and molecular dynamics simulation on a simulation system by means of the Amber software; and performing binding free energy calculation based on a molecular dynamics Poisson-Boltzmann surface area model on a molecular dynamics simulating track in a previous step by means of an MMPBSA.py program.

A method and system is disclosed for estimating the difference between binding free energies of molecules.

The invention belongs to the technical field of pharmacy and relates to an algorithm for quickly and accurately calculating free affinity between proteinase and drug molecules. The algorithm is characterized in that standard chemical potentials of a ligand and receptor in free state and a standard chemical potential of a receptor-ligand complex in bound state are calculated respectively, and differences among the standard chemical potentials are standard binding free energy; wherein in the calculation of the standard chemical potentials, M most steady-state conformations of the molecules are found first, j refers to energy wells corresponding to the most steady-state conformations, with j equal to 1...N, conformation integral zj of the corresponding energy well j of each most steady-state conformation is calculated, corresponding Boltzmann factor RT is calculated accordingly, and all the conformation integrals are combined to obtain a standard chemical potential for the ligand, the receptor or the receptor-ligand complex in bound state. By replacing experiments via computer simulation, screening and optimizing accuracy for pilot drugs are greatly improved, and time and cost for screening and optimizing are greatly decreased.

This invention relates to one method to test earth anode ion even combination free energy and absorptive free energy, which comprises the following steps: a, processing the anode saturation earth adhesive particles with radium less than 2 mu m and then using ion remove water or stilled water to match earth hanging liquid; b, putting the earth hanging liquid into field less than 15kV.cm<-1> to gradually form field intensity to test each conductivity rate to get the relation ship curve between earth hanging liquid and field intensity; c, according to math formula to compute particles anode ion even combination free energy and absorptive free energy, wherein, Delta G=RTln(2CEC.Cp.lambada / EC0) (4); Delta G=RTln(EC / EC0) with R for gas constant; T for thermal temperature and CEC for anode ion exchange volume and Cp for particle concentration.

The invention belongs to the technical field of computer software, discloses a system and method for computing antibody combination mutation evolution, an Information Data Processing Terminal. The computer antibody combinatorial mutation evolution method adopts a genetic algorithm searching strategy, and generates a structural database of combinatorial mutants according to a plurality of amino acid sites in an antibody binding pocket through multiple cycles of calculation, and takes a specific binding free energy function as an affinity evaluation method to automatically evolve to obtain a combinatorial mutation antibody. The computer antibody combinatorial mutation evolution method adopts a genetic algorithm searching strategy, and generates a structural database of combinatorial mutantsaccording to a plurality of amino acid sites in an antibody binding pocket through multiple cycles of calculation, and takes a specific binding free energy function as an affinity evaluation method toautomatically evolve to obtain a combinatorial mutation antibody.

The invention relates to a method for predicting the binding strength of an ultrafiltration membrane surface adsorption unit and a small molecular pollutant. The method particularly comprises the steps of firstly, constructing a structure of a system; then calculating a binding free energy curve of a small molecule and the ultrafiltration membrane surface adsorption unit, and on this basis, figuring out a binding constant. A binding mechanism is obtained by analyzing a binding process, and a theoretical direction is provided for the optimization of the adsorption unit. Results indicate that the calculating result obtained by using the method is accurate, the design cost can be effectively reduced, and the design efficiency is remarkably improved. Thus the theoretical method provided by the invention can be used for predicting the binding strength of the ultrafiltration membrane surface adsorption unit and the small molecular pollutant.

The invention relates to an auxiliary prediction method for molecular modification of antibody protein, which comprises the following steps of: (1) scanning amino acid residuals on a mutual interaction interface of antibodies and antigens; (2) judging microenvironments of the amino acid residuals on the mutual interaction interface of the antibodies and the antigens; (3) determining a candidate reconstruction site, performing virtual mutation to obtain an antigen and mutant antibody complex system, and calculating binding free energy and the change of the binding free energy caused by mutations; and (4) selecting the amino acid residuals possibly having larger impact on affinity and specificity and used as the candidate reconstruction sites according to requirements based on a calculation result of the step (3), and giving a result so as to direct experiments. The method is skillful and unique in design, the statistical rules of the antigen molecular interaction interface are combined, the change of the antigen affinity caused by the mutated antibodies can be predicted qualitatively and quantitatively, the prediction accuracy is greatly improved, and the method is suitable for large-scale promotion and application.

The invention provides pyronaridine compounds and applications thereof. The general formula of the pyronaridine compounds is shown as the formula I, wherein R1, R2, R3, and R4 are acting sites, and therefore the compounds have activity of inhibiting plasmodium in-vivo PDE. The pyronaridine compounds have a binding free energy lower than pyronaridine, and therefore the pyronaridine compounds have higher activity of inhibiting the plasmodium in-vivo PDE than the pyronaridine, and therefore the pyronaridine compounds have stronger anti-malarial activity.

The invention belongs to the technical field of agricultural biotechnologies, and relates to establishment of a cotton bollworm sterol carrier protein 2 (SCP-2) small-molecule inhibitor virtual screening method. The method comprises the following steps: according to structural data of cotton bollworm sterol carrier protein 2 (SCP-2), analyzing a key amino acid residue so as to confirm a binding pocket; screening, scoring and calculating binding free energy by using molecular docking software; performing structure clustering and visual analysis on an obtained compound, thereby obtaining a small-molecule inhibitor for SCP-2 protein. The small-molecule inhibitor can be applied to screening, study and development of novel environmental-friendly pesticides for multiple agricultural pests of lepidoptera as the main target.

A computer-implemented method as follows. Providing a list of target sequences associated with one or more organisms in a list of organisms. Providing a list of candidate prototype sequences suspected of hybridizing to one or more of the target sequences. Generating a collection of probes corresponding to each candidate prototype sequence, each collection of probes having a set of probes for every subsequence having a predetermined, fixed subsequence length of the corresponding candidate prototype sequence. The sets consist of the corresponding subsequence and every variation of the corresponding subsequence formed by varying a center nucleotide of the corresponding subsequence. Generating a set of fragments corresponding to each target sequence, each set of fragments having every fragment having a predetermined, fixed fragment length of the corresponding target sequence. Calculating the binding free energy of each fragment with a perfect complimentary sequence of the fragment. If any binding free energy is above a predetermined, fixed threshold, the fragment is extended one nucleotide at a time until the binding free energy is below the threshold or the fragment is the same length as the probe, generating a set of extended fragments. Determining which extended fragments are perfect matches to any of the probes. Assembling a base call sequence corresponding to each candidate prototype sequence. The base call sequence has a base call corresponding to the center nucleotide of each probe of the corresponding prototype sequence that is a perfect match to any extended fragment, but for which the other members of the set of probes containing the perfect match probe are not perfect matches to any extended fragment and a non-base call in all other circumstances.

The invention relates to a virtual screening method for a micromolecular reversible inhibitor of an alkaline metalloproteinase from flavobacterium YS-80-122 and belongs to the field of marine biotechnologies. The virtual screening method comprises the following steps: determining the type of the micromolecular reversible inhibitor according to the known structural data of the alkaline metalloproteinase from the flavobacterium YS-80-122; measuring the inhibition constant of the micromolecular reversible inhibitor of the type to the alkaline metalloproteinase from the flavobacterium YS-80-122, and determining compounds composing a training set; conducting molecular docking on the compounds of the training set and the alkaline metalloproteinase from the flavobacterium YS-80-122; acquiring the theoretical binding free energy and the theoretical reversible inhibition constant of the compounds of the training set and the alkaline metalloproteinase from the flavobacterium YS-80-122; in combination with the measured data, making a screening rule and establishing a screen model; conducting virtual screening. The virtual screening method is high in screening speed, can quickly reduce the quantity of candidate molecules, and reduce waste of time and test materials.

A computer-implemented method as follows. Providing a list of target sequences associated with one or more organisms in a list of organisms. Providing a list of candidate prototype sequences suspected of hybridizing to one or more of the target sequences. Generating a collection of probes corresponding to each candidate prototype sequence, each collection of probes having a set of probes for every subsequence having a predetermined, fixed subsequence length of the corresponding candidate prototype sequence. The sets consist of the corresponding subsequence and every variation of the corresponding subsequence formed by varying a center nucleotide of the corresponding subsequence. Generating a set of fragments corresponding to each target sequence, each set of fragments having every fragment having a predetermined, fixed fragment length of the corresponding target sequence. Calculating the binding free energy of each fragment with a perfect complimentary sequence of the fragment. If any binding free energy is above a predetermined, fixed threshold, the fragment is extended one nucleotide at a time until the binding free energy is below the threshold or the fragment is the same length as the probe, generating a set of extended fragments. Determining which extended fragments are perfect matches to any of the probes. Assembling a base call sequence corresponding to each candidate prototype sequence. The base call sequence has a base call corresponding to the center nucleotide of each probe of the corresponding prototype sequence that is a perfect match to any extended fragment, but for which the other members of the set of probes containing the perfect match probe are not perfect matches to any extended fragment and a non-base call in all other circumstances.

The present patent relates to a method for qualitative identification and quantitative prediction of thyroid hormone disrupting chemicals base on the interaction between thyroid hormone receptor and co-regulators (coactivator and corepressor).The method identifies chemicals as passive antagonists, active antagonists and agonists by means of co-regulator involved molecular dynamics simulations, and predicts the relative disrupting potencies by use of binding free energy, therefore, may be used for screening of thyroid hormone disruptors among environmental pollutants. Upon more comprehensive consideration of the functioning mechanism of thyroid hormone receptor, the present invention is able to sufficiently identify thyroid hormone disruptors as agonists and antagonists, and gives more accurate prediction of the disrupting potency. Further, since nuclear receptors, just as thyroid hormone receptor, are strongly associated with co-regulators, the method may be expanded to the screening of nuclear receptor mediated endocrine disruptors.

The invention provides a method and device for predicting the binding free energy of protein and ligand molecules, and the method comprises the steps: S1, constructing a local database; s2, analyzingthe data to obtain a ligand molecule and an amino acid molecule in a protein binding pocket taking the ligand molecule as a center; s3, calculating the MACCS secret keys of the ligand molecules and the near amino acids; s4, calculating ECFP fingerprints of ligand molecules and near amino acids; s5, converting the MACCS key and ECFP fingerprint information of the ligand molecule and protein into aone-dimensional tensor to form a training set and a test set; s6, establishing a machine learning model, and training the machine learning model; s7, calculating and comparing a Pearson correlation coefficient and an absolute error, and verifying a prediction result of the machine learning model; and S8, predicting the binding constant of the protein and the ligand molecule by using the trained machine learning model, and calculating the binding free energy. Compared with the prediction result of a single fingerprint, the prediction result of the combined fingerprint is obviously better, and the accuracy of free energy prediction is improved.

The invention relates to a computing method for processing interaction between small molecules and proteins. The method includes the following steps that (1) ligand file data of the proteins and the small molecules are read in; (2) atom types in ligands of the proteins and the small molecules are judged; (3) positions and angles of the ligands of the small molecules are randomly initialized; (4) a search protein algorithm is operated, coordinates and angles of the ligands of the small molecules are optimized, and a chemscore formula serves as an evaluation function; (5) the computing is ended after maximum iterative times are achieved; and (6) results such as root mean square deviation (RMSD), binding free energy delta G and coordinates of a binding site are analyzed and output. Compared with computing methods for processing the interaction between the small molecules and the proteins in prior art, the computing method for processing the interaction between the small molecules and the proteins has the advantages that when pollutants and biomacromolecules are interacted can be rapidly determined, and the like.

The invention discloses a method for calculating protein-ligand binding free energy based on a cluster model, compared with other methods for calculating protein-ligand binding free energy, a GFN2-xTB method is easier to use, an input structure can be formed by only needing initial coordinates and element composition, and when the GFN2-xTB method is combined with the cluster model for application, the input structure is more stable. On the premise of ensuring relatively good accuracy, the time cost of calculation is reduced more effectively. The new method based on the cluster model and the GFN2-xTB should have great potential in calculation of combined free energy related to biomacromolecules in the future.

The invention belongs to the technical field of pharmacy and relates to an algorithm for quickly and accurately calculating free affinity between proteinase and drug molecules. The algorithm is characterized in that standard chemical potentials of a ligand and receptor in free state and a standard chemical potential of a receptor-ligand complex in bound state are calculated respectively, and differences among the standard chemical potentials are standard binding free energy; wherein in the calculation of the standard chemical potentials, M most steady-state conformations of the molecules are found first, j refers to energy wells corresponding to the most steady-state conformations, with j equal to 1...N, conformation integral zj of the corresponding energy well j of each most steady-state conformation is calculated, corresponding Boltzmann factor RT is calculated accordingly, and all the conformation integrals are combined to obtain a standard chemical potential for the ligand, the receptor or the receptor-ligand complex in bound state. By replacing experiments via computer simulation, screening and optimizing accuracy for pilot drugs are greatly improved, and time and cost for screening and optimizing are greatly decreased.

The invention relates to a virtual screening method and device and electronic equipment. The method comprises the following steps: carrying out molecular docking on ligand molecules in a molecular library and target protein to obtain at least one molecular conformation after the ligand molecules are contacted with the target protein; determining first binding free energy after the molecular conformation is contacted with the target protein by adopting a preset scoring function, and screening to obtain the molecular conformation of which the first binding free energy meets a first preset condition; based on a semi-empirical molecular orbital method, respectively determining second binding free energy after the molecular conformation with the first binding free energy meeting a first preset condition is contacted with the target protein, and screening to obtain the molecular conformation with the second binding free energy meeting a second preset condition. According to the scheme provided by the invention, the accuracy of the prediction result can be improved while the binding free energy of the molecular conformation can be rapidly predicted, so that the success rate of screening to obtain the active compound is improved.

The invention provides pyronaridine compounds and applications thereof. The general formula of the pyronaridine compounds is shown as the formula I, wherein R1, R2, R3, and R4 are acting sites, and therefore the compounds have activity of inhibiting plasmodium in-vivo PDE. The pyronaridine compounds have a binding free energy lower than pyronaridine, and therefore the pyronaridine compounds have higher activity of inhibiting the plasmodium in-vivo PDE than the pyronaridine, and therefore the pyronaridine compounds have stronger anti-malarial activity.

The present patent relates to a method for qualitative identification and quantitative prediction of thyroid hormone disrupting chemicals base on the interaction between thyroid hormone receptor and co-regulators (coactivator and corepressor). The method identifies chemicals as passive antagonists, active antagonists and agonists by means of co-regulator involved molecular dynamics simulations, and predicts the relative disrupting potencies by use of binding free energy, therefore, may be used for screening of thyroid hormone disruptors among environmental pollutants. Upon more comprehensive consideration of the functioning mechanism of thyroid hormone receptor, the present invention is able to sufficiently identify thyroid hormone disruptors as agonists and antagonists, and gives more accurate prediction of the disrupting potency. Further, since nuclear receptors, just as thyroid hormone receptor, are strongly associated with co-regulators, the method may be expanded to the screening of nuclear receptor mediated endocrine disruptors.